Adverum Biotechnologies, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Adverum Biotechnologies, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Adverum Biotechnologies, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$27.1M, a 17.5% increase year-over-year.
  • Adverum Biotechnologies, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$94.1M, a 25.4% increase year-over-year.
  • Adverum Biotechnologies, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$117M, a 24.2% increase from 2022.
  • Adverum Biotechnologies, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$155M, a 6.18% decline from 2021.
  • Adverum Biotechnologies, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$146M, a 23.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$94.1M -$27.1M +$5.75M +17.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 -$99.9M -$18.5M +$13M +41.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-04
Q1 2024 -$113M -$24.8M +$4.27M +14.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-04
Q4 2023 -$117M -$23.7M +$9.02M +27.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$126M -$32.9M +$7.25M +18.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 -$133M -$31.5M +$12.3M +28% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-04
Q1 2023 -$146M -$29.1M +$8.85M +23.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-04
Q4 2022 -$155M -$32.7M +$1.67M +4.86% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$156M -$40.1M -$1.77M -4.61% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$154M -$43.8M +$572K +1.29% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$155M -$37.9M -$9.47M -33.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$146M -$34.4M +$3.22M +8.57% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$149M -$38.4M -$10.6M -38.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$138M -$44.3M -$15.1M -51.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$123M -$28.4M -$5.53M -24.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$118M -$37.6M -$18.7M -98.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 -$98.8M -$27.8M -$11.7M -72.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$87.1M -$29.2M -$14.2M -95.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$72.9M -$22.9M -$8.42M -58.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$64.5M -$18.9M -$3.27M -20.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$61.2M -$16.1M +$4.84M +23.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$66.1M -$15M +$3.86M +20.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$69.9M -$14.5M +$2.71M +15.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$72.6M -$15.7M -$870K -5.88% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-06
Q3 2018 -$71.8M -$21M -$7.13M -51.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$64.6M -$18.8M -$7.38M -64.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-07
Q1 2018 -$57.2M -$17.2M -$1.1M -6.84% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-07
Q4 2017 -$56.1M -$14.8M +$7.61M +34% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$63.8M -$13.8M +$472K +3.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-06
Q2 2017 -$64.2M -$11.4M +$50.2M +81.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-06
Q1 2017 -$114M -$16.1M -$707K -4.59% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-06
Q4 2016 -$114M -$22.4M -$8.3M -58.9% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-06
Q3 2016 -$105M -$14.3M -$217K -1.54% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-06
Q2 2016 -$105M -$61.7M -$51.9M -531% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-06
Q1 2016 -$53.3M -$15.4M -$5.88M -61.9% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-06
Q4 2015 -$47.5M -$14.1M -$3.7M -35.6% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-09
Q3 2015 -$43.8M -$14.1M -$5.83M -70.6% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-09
Q2 2015 -$37.9M -$9.77M -$4.67M -91.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-09
Q1 2015 -$33.3M -$9.51M -$7.85M -472% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-09
Q4 2014 -$25.4M -$10.4M -$6.7M -181% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-04
Q3 2014 -$18.7M -$8.26M -$7.44M -915% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-04
Q2 2014 -$11.3M -$5.09M -$4.37M -607% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-04
Q1 2014 -$6.89M -$1.66M -$1.61M -3294% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-04
Q4 2013 -$5.28M -$3.69M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-05
Q3 2013 -$813K Jul 1, 2013 Sep 30, 2013 10-K 2015-03-05
Q2 2013 -$721K Apr 1, 2013 Jun 30, 2013 10-K 2015-03-05
Q1 2013 -$49K Jan 1, 2013 Mar 31, 2013 10-K 2015-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.